Systematic review of urinary tract infections caused by Acinetobacter baumannii: Resistance patterns and clinical outcomes (2020–2025)
Abstract
Urinary tract infections (UTIs) caused by Acinetobacter baumannii have become an important public health concern due to the pathogen’s multidrug-resistant (MDR) nature. Its increasing prevalence in clinical and environmental settings underscores the need to better understand resistance mechanisms, epidemiology, and therapeutic challenges.
Objectives. To systematically review studies published between 2020 and 2025 that investigated the prevalence, antimicrobial resistance patterns, genomic characteristics, and therapeutic strategies for A. baumannii-associated UTIs, with the aim of identifying regional and global trends, resistance determinants, and emerging interventions.
Eligibility criteria. Studies were included if they focused on A. baumannii isolated from UTI cases and reported antimicrobial resistance profiles, genomic analyses, or therapeutic aspects. Only peer-reviewed articles published between January 2020 and May 2025 were considered.
Sources of evidence. Data were retrieved from PubMed, Scopus, and Web of Science using predefined keywords (e.g., “Acinetobacter baumannii,” “urinary tract infection”).
Methods. A standardized data extraction template was used to collect information on study design, geographic location (Iraq [Baghdad, Diyala, Duhok], China, South Korea, and South-East Nigeria), resistance patterns, molecular findings, and potential therapeutic strategies. Study selection and review processes followed PRISMA 2020 guidelines.
Results. The review…
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.